© CAMS Trial 2001 CAMS Study A Multicentre Randomised Controlled Trial of Cannabinoids in Multiple Sclerosis Principle Investigators Dr John Zajicek Dr.

Slides:



Advertisements
Similar presentations
Appraisal of an RCT using a critical appraisal checklist
Advertisements

11 March 2009 Phase III Sativex ® MS Spasticity Trial Study GWSP0604 Preliminary Results.
MS in Plymouth John Zajicek Reader in Neurology, Peninsula Medical School.
Study Design 121 Relapsing-remitting MS patients randomized to –Stress Management Therapy MS active treatment* 16 individual sessions conducted over 24.
Research Study Designs
Antiepileptic Drugs and Suicidality: Background Evelyn Mentari, M.D., M.S. Clinical Safety Reviewer Division of Neurology Products/CDER Food and Drug Administration.
New England Journal of Medicine October 18;367: Relapse Risk after Discontinuation of Risperidone in Alzheimer’s disease Molly Moncrieff.
Compassionate Care NY Vince Marrone. Compassionate Care Act Purpose is to allow New Yorkers with serious medical conditions access to medical marijuana.
Randomised, placebo controlled, double blind, crossover study of the efficacy and side effects of amitriptyline in children 6-18 years old with EB Richard.
Journal Club Usha Niranjan PICU. Rationale 2 x cases of severe dehydration with metabolic acidosis –requesting for HDU management –as given 40mls/kg fluid.
A randomized controlled trial of citalopram on migraine frequency Satnam S. Nijjar, M.D. Department of Neurology, Johns Hopkins School of Medicine.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
Returning Cannabis to the Medicine Cabinet? Professor Les Iversen University of Oxford.
Medical Marijuana A role in the Ataxias? Terry D. Fife, MD, FAAN Director, Balance Disorders & Otoneurology Barrow Neurological Institute Associate Professor.
The Medical Marijuana Maze Chapter One: Introduction Nancy E. Marion Copyright © 2014 Nancy Marion. All rights reserved.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2008.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May-June 2007.
Atorvastatin in Factorial with Omega-3 fatty acid Risk Reduction in Diabetes …in an academic collaboration with.
…in an academic collaboration with ISRCTN
Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2015.
Clinical Trials of Traditional Herbal Medicines In India Y.K.Gupta Professor & Head, Department of Pharmacology, All India Institute of Medical Sciences,
Cannabis Sativa Leaves, flowers, stems, and seeds are smoked, combined with food, or brewed as tea Marijuana – dried leaves and flowers Hashish – concentrated,
SuMS SUM S SuMS S tanding U p in M ultiple S clerosis South West Contacts: Dr Jenny Freeman 
1 Tolvaptan for the Treatment of Hyponatremia Aliza Thompson, MD Medical Officer Cardiovascular and Renal Drugs Advisory Committee Meeting June 25, 2008.
Copyright © 2012 Lippincott Williams & Wilkins. Unauthorized commercial reproduction of this slide is prohibited Supplemental PowerPoint Slides Acupuncture.
Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.
Our Experiences With Natural Natural Products As Potential Therapeutic Agents : Towards Safer & Cost Effective Therapy Dr. Mrs.Chanda Kulkarni. MBBS; MD;
Journal Club May Medical Marijuana Iowa legalizes medicinal marijuana oil for use in treatment of childhood seizures (May 2014) Patients must have.
Background to Adaptive Design Nigel Stallard Professor of Medical Statistics Director of Health Sciences Research Institute Warwick Medical School
Arch Neurol. 2009;66(8): Published online June 8, 2009 (doi: /archneurol ).
Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group,
Ultrasound Guided Botulinum Toxin Injection for Sialorrhoea in Parkinson’s Disease; Evidence, Technique and Outcomes Background Sialorrhoea: inability.
MS: A Perspective on the African American Experience Mary D. Hughes, MD Medical Director, Neuroscience Associates University Medical Group Greenville Hospital.
Statement of the Problem People have pain from chemotherapy and other illnesses because of the lack of options for controlling symptoms relating to a.
Plymouth Health Community NICE Guidance Implementation Group Workshop Two: Debriding agents and specialist wound care clinics. Pressure ulcer risk assessment.
TAP PHARMACEUTICAL PRODUCTS INC. June 2, Arthritis Drugs Advisory Committee TAP Pharmaceutical Products Inc. June 2, 2004.
Stats Review. Identify the appropriate statistic A researcher randomly assigns five individuals to receive a new experimental procedure and five to a.
Efficacy, Hematologic Effects and Dose of Ruxolitinib in Myelofibrosis Patients with Low Platelet Starting Counts ( x 10 9 /L): A Comparison to Patients.
Impact of transient and persistent personality disturbance on the outcome of anxiety and depressive disorders Professor Peter Tyrer (Imperial College,
What is a non-inferiority trial, and what particular challenges do such trials present? Andrew Nunn MRC Clinical Trials Unit 20th February 2012.
A Randomised, Controlled Trial of Acetaminophen, Ibuprofen, and Codeine for Acute Pain relief in Children with Musculoskeletal Trauma Clark et al, Paediatrics.
Trimonabant – tackling a modern epidemic Jusni Saladdin Development Head, Metabolic Diseases.
Mary Jane’s Day By: Sean Asmar CS Why Marijuana should be legalized…..  If the APHA says this “ Concluding that greater harm is caused by the.
Significance Tests Martin Bland Professor of Health Statistics University of York
Symptom control in patients with recurrent ovarian cancer Measuring the benefit of palliative chemotherapy in women with platinum refractory/ resistant.
“Journey of a Drug” From Test Tube TO Prescribing Physician.
CB-1 Background of Pancreatic Cancer & NCIC CTG PA.3 Study Design Malcolm Moore, MD Professor of Medicine and Pharmacology Princess Margaret Hospital Chair,
Efectivness of Spa Therapy in Severe Knee Osteoarthritis; Randomize Controlled Trial Mine Karagülle,MD Istanbul, Turkey.
NHMRC Clinical Trials Centre ANZGOG AGM, 2 April 2009, Noosa NHMRC Clinical Trials Centre Symptom Benefit Study Measuring the Benefit of Palliative Chemotherapy.
Journal Club Neuropsychological effects of levetiracetam and carbamazepine in children with focal epilepsy. Rebecca Luke 2/9/2016.
CLINICAL EFFICACY STUDY OF BACLOFEN IN REDUCING ALCOHOL CONSUMPTION IN HIGH RISK DRINKERS Study title: Alcohol Treatment : A Pragmatic Randomized, Double-blind.
The Relationship Between Chest Tube Size and Clinical Outcome in Pleural Infection Najib M. Rahman, Nicholas A. maskell, Christopher W. H. Davies, Emma.
Analytical Interventional Studies
Fibromyalgia Impact Questionnaire McGill Pain Questionnaire
The DEPression in Visual Impairment Trial:
“MEDICAL” MARIJUANA. “MEDICAL” MARIJUANA So Dude, whassup? What’s out there? SCIENCEY stuff What does it do for/to you? Politics and policy (and what.
Background Over PCIs per year for stable angina
Medical Cannabis Dr. Andrea Burry MSc MD CCFP
Properties of Cannabis
Pharmaceutical- vs Dispensary-Sourced Cannabinoids
MEDICAL CANNABIS 101.
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Evidenced Based Journal Club – 20th June 2007
Clinical Cannabis Interprofessional Education: Program Development and Provider Knowledge Cameron, M.H. 1,2 & Jones, K.D.3,4 1. VA Portland Health Care.
The Research Question Background: Question:
A Review of the Evidence for Medical Cannabis Based on Approved Conditions in Iowa Authors: Ryan Molander, Sarah Kadura, spencer smythe, and nickolas Scott.
PRECEPTOR: RONALD HERMAN
Medical Scientific Experts
Spasticity as measured by mean combined scores on the modified Ashworth scale, before and after treatment, on each day of each phase of the trial. Spasticity.
Flow of recruitment: the screening and enrolment process for a 6-week randomised double-blind placebo-controlled feasibility trial in people with multiple.
Presentation transcript:

© CAMS Trial 2001 CAMS Study A Multicentre Randomised Controlled Trial of Cannabinoids in Multiple Sclerosis Principle Investigators Dr John Zajicek Dr Alan Thompson Andrew Nunn Hilary Sanders

© CAMS Trial 2001 Background - Multiple Sclerosis

© CAMS Trial 2001 Background - MS 90% of patients with Multiple Sclerosis (MS) will experience symptoms of muscle spasticity and spasms. Current therapies for spasticity include baclofen, tizanidine, dantrolene and diazepam. All of these have significant side effects and limited efficacy.

© CAMS Trial 2001 Background - MS Cannabis - widespread anecdotal reports of beneficial effects on –spasticity –tremor –urinary disturbance –pain.

© CAMS Trial 2001 Background - MS Only two previous attempts at randomised double blind controlled studies of cannabinoids in total of 22 patients. Petro and Ellenberger, 1981 –9 patients, 3 days. –THC, double blinded crossover design –significant reduction in spasticity score.

© CAMS Trial 2001 Background - MS Ungerleider et al, 1988 –13 patients, up to 6 weeks –THC, double blinded crossover design –significant reduction in patient rating of spasticity. Thus probably beneficial effect, but too small to generalise.

© CAMS Trial 2001 Background - Cannabis

© CAMS Trial 2001 Background - Cannabis Cannabis sativa - “Cultivated Cannabis” Many uses –Rope –Canvas –Clothing –Paper –Medicinal

© CAMS Trial 2001 Background - Cannabis Medicinal use for over 2000 years. First in the far east. Mentioned in western medical textbooks from the 13th century onwards. The peak in its use was in the 19th century.

© CAMS Trial 2001 Background - Cannabis Indications in 19th century. –Dysmenorrhoea

© CAMS Trial 2001 Background - Cannabis Other Indications. –Pain –Cramps –Fever –Vomiting –Asthma –Epilepsy.

© CAMS Trial 2001 Background - Cannabis Also psychoactive properties. Recreational use.

© CAMS Trial 2001 Background - Cannabis Fell out of use in early 20th century –concern over its recreational use –inconsistency in its preparation and absorption –poor storage stability Formally banned in 1928 Remained prescribable until 1971.

© CAMS Trial 2001 Background - Cannabis Over 60 aromatic hydrocarbon compounds known as cannabinoids. Pharmacological effects mediated through cannabinoid receptors –CB1 receptors are found widely in the nervous system –CB2 receptors predominantly on B lymphocytes.

© CAMS Trial 2001 Background - Cannabis THC - most important active cannabinoid. Available synthetically. Prescribable for nausea as nabilone.

© CAMS Trial 2001 Background - Cannabis House of Lords Select Committee report - “Cannabis, the scientific and medical evidence”. Positive about medicinal use. Advised further research before rescheduling of the drug.

© CAMS Trial 2001 Trial Design

© CAMS Trial 2001 Trial Design Multicentre randomised controlled trial. Comparing THC, cannabis oil and placebo. Coordinated from Plymouth –Derriford will recruit approximately 100 patients –560 patients distributed across about 20 other centres nationwide.

© CAMS Trial 2001 Trial Design - Centres

© CAMS Trial 2001 Trial Design Two Phases –Weeks 1-16 All patients on drug Seven clinic visits –Weeks Patient chooses whether to continue drug Three clinic visits

© CAMS Trial 2001 Trial Design

© CAMS Trial 2001 Primary Outcome Measures Ashworth Scale –5 grade assessment of spasticity on clinical examination. –Rather coarse steps. –Rather subjective. –Reasonable inter- and intra- rater reliability.

© CAMS Trial 2001 Secondary Outcome Measures Timed 10m walk Rivermead Mobility Index UK Neurological Disability Status Scale GHQ-30 (a quality of life questionnaire) Barthel Index (a measure of activities of daily living) 9 further category rating scales.

© CAMS Trial 2001 Blinding Risk of unblinding of patient due to widely known side effects. Two study personnel. –Treating physician –Assessor (physician or physiotherapist) Degree of unblinding assessed at the end of the trial.

© CAMS Trial 2001 Results Recruitment will start at beginning of Recruitment expected to last about 1 year. Results available 1 year after recruitment closes. Government has indicated that a successful trial may lead to rescheduling of cannabis.

© CAMS Trial 2001 Further Information References & general information: – Telephone: –